Michelle Monaghan Champions Skin Health in New Awareness Campaign
NEW YORK, May 30, 2025 /PRNewswire/ — Healthy skin is more than surface-level, it's a key part of our overall well-being. That's why Mediaplanet is proud to launch its 'Skin Health' campaign, aimed at empowering individuals to take charge of their skin through education, prevention, and smart skincare choices. From early detection to everyday sun protection, this campaign emphasizes that maintaining healthy skin is a lifelong commitment.
Skin is our body's largest organ, yet it's often overlooked when it comes to proactive care. This campaign is designed to change that by delivering expert guidance, highlighting innovative dermatological advances, and sharing practical tips for every age and skin type. Whether you're managing a chronic condition or simply want to build better daily habits, the 'Skin Health' campaign offers resources to help you prioritize long-term skin wellness.
Featuring cover story Michelle Monaghan, the campaign brings a personal and powerful voice to the conversation. The award-winning actress opens up about her experience with skin cancer, how motherhood reshaped her view on sun safety, and the importance of early detection. In her exclusive interview, Monaghan shares the simple yet critical habits she relies on — like daily sunscreen use and routine skin checks — while encouraging others to take their skin health seriously.
The print component of 'Skin Health' is distributed in today's edition of USA Today. The digital component is distributed nationally, through a vast social media strategy, and across a network of top news sites and partner outlets. To explore the digital version of the campaign, visit: https://www.futureofpersonalhealth.com/campaign/skin-health/
This campaign was made possible with the support of Michelle Monaghan, Jennie Garth, Dr. Charles, MD, Dr. Jenny Liu, M.D., FAAD, Dr. Lindsey Zubritsky, M.D., FAAD, Dr. Mamina Turegano, M.D., FAAD, the Skin Cancer Foundation, the American Society for Dermatologic Surgery, the Society for Pediatric Dermatology, the Society of Cosmetic Chemists, the Coalition of Skin Diseases, the National Foundation for Ectodermal Dysplasias and features paid content from the Melanoma Research Foundation, Castle Biosciences, GentleCure & Sciton.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
4 hours ago
- Malaysian Reserve
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The L
Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2 PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ — Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in The Lancet.1 In a phase 1b/2a clinical trial of 125 adults with overweight or obesity, once-weekly subcutaneous amycretin appeared to be safe and tolerable in trial participants, who also achieved significantly greater weight loss across the full range of doses investigated versus placebo.1 A related phase 1 trial of once-daily oral amycretin in adults with obesity or overweight also showed that treatment was safe and tolerable with an observed reduction in body weight compared to placebo.2 No weight loss plateau was observed in either trial at the end of the respective treatment durations.1,2 Data on subcutaneous amycretin is scheduled to be presented on Sunday, June 22nd, during a late-breaking poster session at the American Diabetes Association's® (ADA) 85th Scientific Sessions.1 'We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management. At Novo Nordisk, we understand that addressing obesity is a complex challenge that many patients face. These results reflect our robust pipeline in obesity, our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk. 'We remain steadfast in our mission to discover and develop therapies that can have a meaningful impact in the lives of those affected by obesity.' Results from the phase 1b/2a trial of subcutaneous amycretin showed treatment-emergent adverse events (TEAEs) were mild or moderate in severity and increased in frequency in a dose-dependent manner. The most frequent reported TEAEs were gastrointestinal in nature. Compared to placebo, participants receiving amycretin observed greater weight loss across the full range of doses investigated.1 Subcutaneous amycretin at multiple doses demonstrated greater weight reduction than placebo at the end of the trial. Participants who received the highest doses (up to 60 mg) reported body weight reductions of up to 24.3% versus 1.1% with placebo after 36 weeks of treatment. Results from this first-in-human phase 1b/2a study support further investigation of potential weight-loss efficacy of amycretin. Results from the published phase 1 trial of oral amycretin showed that the most common TEAEs were related to gastrointestinal symptoms (mainly nausea and vomiting) and decreased appetite; these were most frequent for the higher doses. Trial participants receiving the study treatment demonstrated significantly greater weight loss across the full range of doses investigated versus the placebo group.2 Exploratory results showed participants taking 100 mg per day of oral amycretin achieved a mean weight loss of 13.1% versus 1.2% with placebo after 12 weeks.2 Based on these phase 1 results, longer evaluation with more participants is warranted to substantiate the full efficacy findings of oral amycretin on body weight reductions and changes in metabolic parameters. Novo Nordisk will advance both subcutaneous and oral amycretin formulations straight to phase 3 development for weight management based on these and other completed clinical studies, as well as feedback received from regulatory authorities. About amycretinAmycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is under investigation for oral and subcutaneous administration, and is not approved in the US for weight loss. About the phase 1b/2a subcutaneous amycretin trialThe phase 1b/2a trial was a randomized, placebo-controlled, single-center, double-blinded study of 125 participants assessing the safety, tolerability, pharmacokinetics, and effects on body weight after subcutaneous administration of amycretin in people with overweight or obesity.1 Adults with a body mass index of 27-39.9kg/m2 and glycated hemoglobin (HbA1c) <6.5% were eligible for the trial.1 The trial was conducted in 5 parts: a single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B).1 Lastly, in the multiple ascending dose – dose response parts, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).1 About the phase 1 oral amycretin trial The phase 1 single-center, randomized, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (Part A) and multiple ascending doses (Part B, 10 days of treatment; Part C/D, 12 weeks of treatment) of 144 adult participants with overweight or obesity.2 The primary endpoint was the number of treatment-emergent adverse events (TEAEs) observed in the trial. The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.2 About obesityObesity is a serious chronic, progressive, and complex disease that requires long-term management.3-5 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.3,5 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.6,7 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.8,9 In the US, about 40% of adults live with obesity.10 About Novo NordiskNovo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information Media: Liz Skrbkova (US)+1 609 917 0632USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Investors: Frederik Taylor Pitter (US)+1 609 613 0568fptr@ Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@ Sina Meyer (Global)+45 3079 6656 azey@ Ida Schaap Melvold (Global)+45 3077 5649 idmg@ Max Ung (Global)+45 3077 6414mxun@ References Dahl K, Toubro S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: Results of a randomised, controlled, phase 1b/2a study. The Lancet. Published online: June 20, 2025. Gasiorek A, Heydorn A, Gabery S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, randomised, placebo-controlled study. The Lancet. Published online: June 20, 2025. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61-69. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Rev. 2017;18(7):715-723. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1-203. Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: June 2025. Available at: World Obesity Federation. World Obesity Atlas 2023. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Why it matters. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023. Last accessed June 2025. Available at: © 2025 Novo Nordisk All rights reserved. US25SEMO01477 June 2025
Malaysian Reserve
7 hours ago
- Malaysian Reserve
Johnson Pope Expands Legal Talent with the Addition of Jessica Warwick and Samuel C. Craig to Its St. Petersburg Office
ST. PETERSBURG, Fla., June 20, 2025 /PRNewswire/ — Johnson, Pope, Bokor, Ruppel & Burns, LLP is proud to announce the addition of two new associate attorneys, Jessica Warwick and Samuel C. Craig, to its St. Petersburg office. These strategic hires reflect the firm's continued growth and commitment to serving clients with deep, specialized knowledge across key practice areas. Jessica Warwick Joins Healthcare Practice GroupJessica Warwick has joined Johnson Pope's Healthcare Practice Group, where she advises hospitals, health systems, and medical providers on a wide range of regulatory and compliance matters. Her areas of focus include telemedicine, the corporate practice of medicine, and Medicare/Medicaid compliance. Jessica holds both a Juris Doctor and a Master of Health Administration from Penn State. Her experience includes drafting and negotiating management and professional services agreements, conducting regulatory compliance reviews for digital health platforms, and supporting healthcare M&A transactions. Jessica is admitted to the Florida Bar and currently serves as the Health and Wellness Chair for the Pinellas County chapter of the Florida Association for Women Lawyers. Samuel C. Craig Joins Tax, Trusts & Estates Practice GroupsSamuel C. Craig has joined Johnson Pope as an associate in the Tax, Trusts & Estates and Business Transactions Practice Groups. Sam focuses his practice on estate planning, tax law, and business matters, providing practical, strategic counsel to individuals, families, and business owners. Sam earned his J.D. from Stetson University College of Law, where he was a research assistant, president of the Business Law Society, and a member of both the Dispute Resolution Board and Trial Team. He received multiple awards for oral advocacy, including a national mock trial championship and induction into the National Order of the Barristers. He later earned his LL.M. in Taxation from the University of Florida on a merit scholarship where he earned multiple CALI book awards, further honing his knowledge of federal and state tax law. Sam is dedicated to helping clients protect their legacies, minimize tax burdens, and navigate complex legal issues with clarity and care. About Johnson PopeJohnson, Pope, Bokor, Ruppel & Burns, LLP is a full-service Florida-based law firm with offices in Tampa, Clearwater, and St. Petersburg. The firm is known for its commitment to excellence, innovative legal solutions, and deep roots in the communities it serves. To learn more, visit
Malaysian Reserve
a day ago
- Malaysian Reserve
Infectious Disease Testing Market Remains Dynamic Amid Post-Pandemic Shifts and New Innovations
ARLINGTON, Va., June 19, 2025 /PRNewswire/ — Kalorama Information, a trusted source for healthcare market intelligence, released insights into the evolving global market for infectious disease testing through the In Vitro Diagnostics Business Outlook newsletter. Despite the decline in COVID-19 testing, the overall infectious disease diagnostics market remains robust, supported by sustained demand for non-COVID tests and the adoption of next-generation technologies across both laboratory and point-of-care (POC) settings. With testing essential for diagnosing, monitoring, and containing a wide range of infections—from respiratory illnesses and bloodborne viruses to sepsis and gastrointestinal pathogens—the market continues to attract significant attention and investment. Kalorama's latest report highlights a steady shift in growth drivers, with POC solutions, molecular platforms, and advanced immunoassays gaining ground. 'Infectious disease diagnostics continues to be one of the most innovative segments of the IVD industry,' said Daniel Granderson, Senior Editor of Kalorama Information. 'New technologies are not only enhancing diagnostic speed and accuracy but are also reshaping where and how testing is performed—bringing more solutions to decentralized and resource-limited settings.' Highlights from the article include: Strong global demand for lab-based immunoassays and molecular tests Continued innovation in syndromic panels, microfluidics, and cartridge-based POC platforms A growing share of the market shifting toward emerging regions, with Asia Pacific and other developing areas seeing increased diagnostic infrastructure and demand Major industry players—including Roche, Abbott, Danaher, and QIAGEN—introducing new products to address unmet needs in STIs, sepsis, and respiratory diseases The report also profiles emerging innovators bringing AI-powered diagnostics, rapid sepsis panels, and cost-effective molecular tools to market, emphasizing the industry's ongoing focus on speed, accuracy, and accessibility. For more insights on market forecasts, regional dynamics, and comprehensive market views, visit Kalorama Information's IVD Business Outlook. About IVD Business Outlook In Vitro Diagnostics Business Outlook is a bimonthly publication from Kalorama Information, offering six issues annually—each dedicated to a distinct segment of the IVD industry. Designed for decision-makers across diagnostics and life sciences, the publication delivers exclusive market intelligence, including growth forecasts, market sizing, and share analysis. Each issue features in-depth coverage of diagnostic test categories, company profiles, mergers and acquisitions, regional trends, and expert analysis of key industry developments. With curated insights not found in mainstream sources, In Vitro Diagnostics Business Outlook is an essential resource for staying ahead in the global diagnostics market. About Kalorama InformationKalorama Information, a division of Science and Medicine Group, is a leading provider of healthcare market research, delivering actionable intelligence to diagnostics, biotechnology, medical device, and pharmaceutical companies worldwide. Website:
